In this sense, protein kinase B or AKT, a serine/threonine kinase that requires a functional phosphoinositide kinase (PI3K) to be activated, has been considered as an essential target for neuroprotective therapies after ischemia [17,18]. The gene discussed is AKT1; the disease is ischemia.